VanEck Biotech ETF
BBH
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 666 Third Avenue, 9th Floor New York NY United States of America 10017
- IPO Date
- Nov 23, 1999
- CIK
- 0001137360
- Website
- vaneck.com
- Similar Companies
- Business
- VanEck Biotech ETF (BBH) is an exchange-traded fund that seeks to replicate the price and yield performance, before fees and expenses, of the MVIS US Listed Biotech 25 Index. The index tracks the overall performance of the 25 largest and most liquid companies involved in the development, production, marketing, and sales of drugs based on genetic analysis and diagnostic equipment; biotechnology research and development services; and diagnostic equipment and related supplies. The fund holds a concentrated portfolio of approximately 25 stocks, weighted by market capitalization, with top holdings including Amgen Inc. (13%), Gilead Sciences Inc. (11.5%), Vertex Pharmaceuticals Inc. (9.6%), Regeneron Pharmaceuticals Inc. (5.8%), and Insmed Inc. (5.4%), primarily in the healthcare sector (99.92% allocation). BBH provides exposure to U.S.-listed domestic and foreign biotechnology firms, with geographic weightings led by the United States (90.9%), followed by China (3.9%), Ireland (3%), and Germany (2.1%). Launched on December 20, 2011, and managed by VanEck ETF Trust, BBH is domiciled in the United States with headquarters aligned to VanEck's operations in New York. The fund targets institutional and retail investors seeking concentrated exposure to leading biotech companies, emphasizing high liquidity based on market cap and trading volume. As of December 2025, BBH manages approximately $377 million in net assets with a total expense ratio of 0.35% and a trailing twelve-month dividend yield of about 0.66%. In recent developments, BBH declared its annual distribution of $1.2517 per share in December 2024, marking an increase from $0.71 in 2023 and reflecting improved portfolio yields. The fund has posted strong performance, with year-to-date returns of 21.04% and one-year returns of 19.18% as of December 16, 2025, fueled by rallies in holdings like Moderna amid biotech sector recovery. Assets under management grew to $377 million by late 2025 from around $351 million earlier in the year, supported by inflows amid positive healthcare sector momentum, though no major acquisitions, partnerships, or structural changes specific to the ETF were reported in the last 1-2 years.